Sales Support
U.S.:+1-415-871-0703
U.K.:+44-203-289-4040
AUS.: +61-2-4786-0457
INDIA:+91-848-285-0837
Contact Us
We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Myelodysplastic Syndrome (MDS) Treatment market 2020 BY MANUFACTURERS, REGIONS, TYPE AND APPLICATION, FORECAST TO 2026

  • Purchase Options

 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around 30% of the patients, known as Acute Myeloid Leukemia (AML). MDS is most commonly found in aging population and remains an incurable disease in majority of patients. According to the American Cancer Society, over 13,000 new cases of MDS occur in the U.S. every year. This is expected to drive the growth of myelodysplastic syndrome treatment market. Hypomethylating drugs such as azacitidine and decitabine help stimulate blood cells to mature and improve blood cell production in MDS.
Market Dynamics
According to the American Society of Hematology, in 2016, prevalence of MDS ranged from 0.22-13.2 per 100,000, on all age categories and ethnicities globally. Increasing public awareness about the disease and introduction of new treatment for MDS will drive the growth of the market. Furthermore, growing aging population is analyzed to be a major factor propelling the growth of myelodysplastic syndrome treatment market. According to NCBI, 2012, the incidence of MDS increases significantly with age and the disease is most prevalent in males. Besides, companies such as Celgene and Novartis, who offer innovative brands in this market would be able to combat the loss of share, post patent expiry through their pipeline molecules expected to be launched during the forecast period.
Market Taxonomy
This report segments the global myelodysplastic syndrome treatment market on the basis of drugs. On the basis of drugs, the global Myelodysplastic syndrome treatment market is classified into Azacitidine, Lenalidomide, Decitabine, and Deferasirox. For comprehensive understanding of market dynamics, the global myelodysplastic syndrome treatment market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.
Key features of the study:
• This report provides in-depth analysis of myelodysplastic syndrome treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 - 2025), considering 2016 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global myelodysplastic syndrome treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
• Key companies covered as a part of this study include Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd, Mylan N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
• The global myelodysplastic syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, Myelodysplastic syndrome treatment manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the myelodysplastic syndrome treatment market
Detailed Segmentation:
• Global Myelodysplastic syndrome treatment market, By Drug:
o Azacitidine
o Lenalidomide
o Decitabine
o Deferasirox
• Global Myelodysplastic syndrome treatment market, By Geography:
o North America
 By Country
 U.S.
 Canada
 By Drug
 Azacitidine
 Lenalidomide
 Decitabine
 Deferasirox
o Europe
 By Country
 Germany
 Italy
 France
 Russia
 Rest of the Europe
 By Drug
 Azacitidine
 Lenalidomide
 Decitabine
 Deferasirox
o Asia Pacific
 By Country
 China
 Japan
 ASEAN
 Australia
 South Korea
 Rest of Asia Pacific
 By Drug
 Azacitidine
 Lenalidomide
 Decitabine
 Deferasirox
o Latin America
 By Country
 Mexico
 Rest of Latin America
 By Drug
 Azacitidine
 Lenalidomide
 Decitabine
 Deferasirox
o Middle East
 By Country
 GCC
 Israel
 By Drug
 Azacitidine
 Lenalidomide
 Decitabine
 Deferasirox
o Africa
 By Country
 North Africa
 Central Africa
 South Africa
 By Drug
 Azacitidine
 Lenalidomide
 Decitabine
 Deferasirox
• Company Profiles
o Novartis AG*
 Company Overview
 Product Portfolio
 Financial Performance
 Key Strategies
 Recent Developments
 Future Plans
o Celgene Corporation
o Otsuka Pharmaceutical Co., Ltd.
o Sandoz Inc.
o Dr Reddys Laboratories Limited
o Pharmascience Inc
o Accord Healthcare Ltd
o Mylan N.V.
"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents
1. Research Objective and assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
? Market Definition and Scope
o Executive Summary
? Market Snippet By Drug
? Market Snippet By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
? Drivers
? Supply Side Drivers
? Demand Side Drivers
? Economic Drivers
? Restraints
? Market Opportunities
? Regulatory Scenario
? Epidemiology/Prevalence/Incidence
? Product Pipeline
4. Global Myelodysplastic syndrome Treatment Market, By Drug, 2015 - 2025 (USD Million)
o Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, 2017 - 2025
? Segment Trends
o Azacitidine
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
o Lenalidomide
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
o Decitabine
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
o Deferasirox
? Introduction
? Market Size and Forecast, and Y-O-Y Growth, 2017 - 2025, (USD Million)
5. Global Myelodysplastic syndrome Treatment Market, By Regions, 2015 - 2025 (USD Million)
o Introduction
? Market Share Analysis, By Region, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, For Regions, 2017 - 2025
o North America
? Market Share Analysis, By Country, 2017 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2017 - 2025
? U.S.
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Canada
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Market Share Analysis, By Drug, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Drug, 2017 - 2025
? Azacitidine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Lenalidomide
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Decitabine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Deferasirox
? Market Size and Forecast, 2015 - 2025 (USD Million)
o Europe
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2017 - 2025
? U.K.
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Germany
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Italy
? Market Size and Forecast, 2015 - 2025 (USD Million)
? France
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Russia
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Rest of the Europe
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Market Share Analysis, By Drug, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Drug, 2017 - 2025
? Azacitidine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Lenalidomide
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Decitabine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Deferasirox
? Market Size and Forecast, 2015 - 2025 (USD Million)
o Asia Pacific
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2017 - 2025
? China
? Market Size and Forecast, 2015 - 2025 (USD Million)
? India
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Japan
? Market Size and Forecast, 2015 - 2025 (USD Million)
? ASEAN
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Australia
? Market Size and Forecast, 2015 - 2025 (USD Million)
? South Korea
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Rest of Asia Pacific
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Market Share Analysis, By Drug, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Drug, 2017 - 2025
? Azacitidine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Lenalidomide
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Decitabine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Deferasirox
? Market Size and Forecast, 2015 - 2025 (USD Million)
o Latin America
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2017 - 2025
? Brazil
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Mexico
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Rest of Latin America
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Market Share Analysis, By Drug, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Drug, 2017 - 2025
? Azacitidine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Lenalidomide
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Decitabine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Deferasirox
? Market Size and Forecast, 2015 - 2025 (USD Million)
?
o Africa
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2017 - 2025
? Northern Africa
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Central Africa
? Market Size and Forecast, 2015 - 2025 (USD Million)
? South Africa
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Market Share Analysis, By Drug, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Drug, 2017 - 2025
? Azacitidine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Lenalidomide
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Decitabine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Deferasirox
? Market Size and Forecast, 2015 - 2025 (USD Million)
?
o Middle East
? Market Share Analysis, By Country, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Country, 2017 - 2025
? GCC Countries
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Israel
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Market Share Analysis, By Drug, 2016 and 2025 (%)
? Y-O-Y Growth Analysis, By Drug, 2017 - 2025
? Azacitidine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Lenalidomide
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Decitabine
? Market Size and Forecast, 2015 - 2025 (USD Million)
? Deferasirox
? Market Size and Forecast, 2015 - 2025 (USD Million)
6. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
? Novartis AG
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Celgene Corporation
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Otsuka Pharmaceutical Co., Ltd.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Sandoz Inc.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Dr Reddys Laboratories Limited
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Pharmascience Inc
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Accord Healthcare Ltd
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
? Mylan N.V.
? Company Overview
? Product Portfolio
? Financial Performance
? Recent Developments/Updates
? Future Plans
o Analyst Views
7. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 45 market data tables and 23 figures on "Myelodysplastic Syndrome Treatment Market - Global forecast to 2025".

 

  • Purchase Options

  • Happy To Assist You

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.

Contact us